Information into Clinical Care - CLL and Bispecific Antibodies in the Management of Lymphoma

What I Tell My Patients: Integrating New Research Information into Clinical Care - CLL and Bispecific Antibodies in the Management of Lymphoma
Proceedings from a live event on April 25, 2024, held during the 2024 Annual ONS Congress and moderated by Dr Neil Love. Featuring perspectives from Dr John N Allan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran. Published June 14, 2024.
Topics:
• Introduction (0:00)
• First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) (11:44)
• The Impact of Comorbid Conditions on the Choice of First-Line Therapy for Newly Diagnosed CLL (18:08)
• Toxicities and Other Practical Considerations with Venetoclax-Based Treatment (25:17)
• The Selection and Sequencing of Therapies for Relapsed/Refractory CLL (35:45)
• The Tolerability of Available Bruton Tyrosine Kinase (BTK) Inhibitors (40:43)
• The Potential Role of Therapy Combining BTK Inhibitors and Venetoclax (48:48)
• Bispecific Antibodies as a Treatment Option for Non-Hodgkin Lymphoma (1:04:19)
• Cytokine Release Syndrome and Neurotoxicity with Bispecific Antibodies (1:06:25)
• Other Tolerability and Toxicity Issues with Bispecific Antibody Therapy (1:10:44)
• Bispecific Antibodies for the Management of Follicular Lymphoma (1:18:19)
• The Role of Bispecific Antibody Therapy in the Treatment of Diffuse Large B-Cell Lymphoma (1:24:17)
• Other Practical Considerations with the Use of Bispecific Antibodies (1:40:59)
The full program, slides, CME information, and select publications:
www.researchtopractice.com/ON...